A study to evaluate, by country and overall, the changes from baseline of the irritable bowel syndrome quality of life (IBS QoL) total score after 4 and 8 weeks of treatment with Duspatalin® or Dicetel® in IBS patients.
Study Type
OBSERVATIONAL
Enrollment
607
Site reference ID/Investigator# 94519
Beijing, China
Change in Irritable Bowel syndrome (IBS) quality of life (QoL) measure (IBS-QoL) to assess the impairment of QoL in IBS patients
Time frame: From baseline up to the week 8 visit
Change in abdominal pain
Time frame: From baseline up to the week 8 visit
Change in bloating
Time frame: From baseline up to the week 8 visit
Change in feeling of abdominal distension
Time frame: From baseline up to the week 8 visit
Change in stool frequency
Time frame: From baseline up to the week 8 visit
Change in stool form
Time frame: From baseline up to the week 8 visit
Change in straining of evacuation
Time frame: From baseline up to the week 8 visit
Change in urgency of evacuation
Time frame: From baseline up to the week 8 visit
Change in feeling of incomplete evacuation
Time frame: From baseline up to the week 8 visit
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Site reference ID/Investigator# 94521
Guangzhou, China
Site reference ID/Investigator# 95475
Guangzhou, China
Site reference ID/Investigator # 94518
Shanghai, China
Site reference ID/Investigator # 94517
Shanghai, China
Site reference ID/Investigator # 94516
Shanghai, China
Site reference ID/Investigator # 94515
Wuhan, China
Site Reference ID/Investigator# 95908
Alexandria, Egypt
Site reference ID/Investigator# 95900
Cairo, Egypt
Site reference ID/Investigator# 95901
El Sharkya, Egypt
...and 14 more locations